Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study
Melcangi et al., 2019
“our results demonstrate methylation of SRD5A2 promoter in a tissue specific manner in PFS patients.”
This pilot study reported a finding of gene promoter methylation of SRD5A2 in CSF samples of 9 of 16 PFS patients (age 34.5 ± 8.8 years) compared with 1 of 13 age-matched controls. Interestingly, the single control with SRD5A2 methylation had a diagnosis of normotensive hydrocephalus.
Amongst PFS patients the methylation ranged from 15.4 to 100%. Neither depression, anxiety or erectile dysfunction scoring via validated scales were correlated to methylation status. Methylation was not found in blood DNA, demonstrating tissue specificity. SRD5A1 was found to be unmethylated across samples and groups.
